Abstract
Species-specific differences in the enzymatic inactivation of peptides is an important consideration in the evaluation of therapeutic efficacy. We demonstrate that glucagon-like peptide 2 (GLP-2), shown to be highly intestinotrophic in mice, promotes an increase in intestinal villus height but has no trophic effect on small bowel weight in rats. The reduced intestinotrophic activity of GLP-2 in rats is attributable to inactivation by the enzyme dipeptidyl peptidase IV (DPP-IV). GLP-2(1-33) was degraded to GLP-2(3-33) following incubation with human placental DPP-IV or rat serum but not by serum from DPP-IV-deficient rats. Administration of rat GLP-2 to DPP-IV-deficient rats was associated with markedly increased bioactivity of rat GLP-2 resulting in a significant increase in small bowel weight. A synthetic GLP-2 analog, r[Gly2]GLP-2, with an alanine to glycine substitution at position 2, was resistant to cleavage by both DPP-IV and rat serum in vitro. Treatment of wild&-type rats with r[Gly2]GLP-2 produced a statistically significant increase in small bowel mass. DPP-IV-mediated inactivation of GLP-2 is a critical determinant of the growth factor-like properties of GLP-2.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Taylor, R.G. and Fuller, P.J. 1994. Humoral regulation of intestinal adaptation. Baillieres Clin. Endocrinol. and Metab. 8: 165–183.
Gleeson, M.H., Bloom, S.R., Polak, J.M., Henry, K., and Dowling, R.H. 1971. Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function. Gut 12: 773–782.
Stevens, F.M., Flanagan, R.W., O'Gorman, D., and Buchanan, K.D. 1984. Glucagonoma syndrome demonstrating giant duodenal villi. Gut 25: 784–791.
Bloom, S.R. and Polak, J.M. 1982. The hormonal pattern of intestinal adaptation [a major role for enteroglucagon]. Scand. J. Gastroenterol. 17: 93–103.
Fuller, P.J., Beveridge, D.J., and Taylor, R.G. 1993. lleal proglucagon gene expression in the rat: characterization in intestinal adaptation using in situ hybridization. Gastroenterology 104: 459–466.
Besterman, H.S., Adrian, T.E., Mallinson, C.N., Christofides, N.D., Sarson, D.L., and Pera, A. et al. 1982. Gut hormone release after intestinal resection. Gut 23: 854–861.
Ehrlich, P., Tucker, D., Asa, S.L, Brubaker, P.L, and Drucker, D.J. 1994. Inhibition of pancreatic proglucagon gene expression in mice bearing subcutaneous endocrine tumors. Am. J. Physiol. Endocrinol. Metab. 267: E662–E671.
Drucker, D.J., Ehrlich, P., Asa, S.L, and Brubaker, P.L. 1996. Induction of intestinal epithelial proliferation by glucagon–like peptide 2. Proc. Natl. Acad. Sci. USA 93: 7911–7916.
Tsai, C.-H., Hill, M. and Drucker, D.J. 1997. Biological determinants of intestinotrophic properties of GLP-2 in vivo. Am. J. Physiol. 272: G662–G668.
Kieffer, T.J., Mclntosh, C.H.S., and Pederson, R.A. 1995. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucaoon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136: 3585–3596.
Deacon, C.F., Johnsen, A.H., and Hoist, J.J. 1995. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol.Metab. 80: 952–957.
Watanabe, Y., Kojima, T, and Fujimoto, Y. 1987. Deficiency of membrane-bound dipeptidyl aminopeptidase IV in a certain rat strain. Experientia 43: 400–401.
Thompson, N.L., Hixson, D.C. Callanan, H., Panzica, M., Flanagan, D., Faris, R.A., et al. 1991. A Fischer rat substrain deficient in dipeptidyl peptidase IV activity makes normal steady-state RNA levels and an altered protein. Biochem. J. 273: 497–502.
Bongers, J., Lambros, T, Ahmad, M. and Heimer, E.P. 1992. Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. Biochim. Biophys. Acta 1122: 147–153.
Frohman, L.A., Downs, T.R., Heimer, E.P. and Felix, A.M. 1989. Dipeptidyl peptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J. Clin. Invest. 83: 1533–1540.
Lance, V.A. Murphy, W.A. Sueiras-Diaz, J., Coy, D.H. 1984. Super-active analogues of growth hormone-releasing factor (1-29)-amide. Biochem. Biophys. Res. Commun. 119: 265–272.
Frohman, L.A., Downs, T.R., Williams, T.C., Heimer, E.R, Pan, Y-C.E., and Felix, A.M. 1986. Rapid enzymatic degradation of growth hormone releasing factor by plasma in vivo and in vivo to a biologically inactive product cleaved at the NH2-terminuss. J. Clin. Invest. 78: 906–913.
Mentlein, R., Gallwitz, B., and Schmidt, W.E. 1993. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214: 829–835.
Knudsen, L.B. and Pridal, L. 1996. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1 -(7-36) amide after in vivo administration to dogs and it acts as an antagonist on the pancreatic receptor. Eur. J. Pharmacol. 318: 429–435.
Thompson, N.L., Hixson, D.C. Callanan, H. Panzica, M. Flanagan, D. Paris, R.A. et al. 1991. A Fischer rat substrain deficient in dipeptidyl peptidase IV activity makes normal steady-state RNA levels and an altered protein. Use as a liver-cell transplantation model. Biochem. J. 273: 497–502.
Erickson, R.H., Suzuki, Y, Sedlmayer, A. and Kirn, Y.S. 1992. Biosynthesis and degradation of altered immature forms of intestinal dipeptidyl peptidase IV in a rat strain lacking the enzyme. J. Bid. Chem. 267: 21623–21629.
Hildebrandt, M., Reutter, W., Gitlin, J.D. 1991. Tissue-specific regulation of dipeptidyl peptidase IV expression during development. Biochem. J. 277: 331–334.
Darmoul, D., Voisin, T., Couvineau, A., Rouyer-Fessard, C., Salomon, R., and Wang, Y. et al. 1994. Regional expression of epithelial dipeptidyl peptidase IV in the human intestines. Biochem. Biophys. Res. Commun. 203: 1224–1229.
Bai, J.P.F. 1994. Distribution of brush-border membrane peptidases along the rat intestine Pharm. Res. 11: 897–900.
Darmoul, D., Rouyer-Fessard, C., Blais, A., Voisin, T., Sapin, C., Baricault, L. et al. 1991. Dipeptidyl peptidase IV expression in rat jejunal crypt-villus axis is controlled at mRNA level. Am. J. Physiol. 261: G763–G769.
Orskov, C. and Hoist, J.J. 1987. Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand. J.Clin. Lab. Invest. 47: 165–174.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Drucker, D., Shi, Q., Crivici, A. et al. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol 15, 673–677 (1997). https://doi.org/10.1038/nbt0797-673
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nbt0797-673
This article is cited by
-
Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
Scientific Reports (2023)
-
Therapeutic Potential of GLP-2 Analogs in Gastrointestinal Disorders: Current Knowledge, Nutritional Aspects, and Future Perspectives
Current Nutrition Reports (2022)
-
Combining mass spectrometry and machine learning to discover bioactive peptides
Nature Communications (2022)
-
The Long Road to the Development of Effective Therapies for the Short Gut Syndrome: A Personal Perspective
Digestive Diseases and Sciences (2019)
-
Impact of bariatric surgery on type 2 diabetes: contribution of inflammation and gut microbiome?
Seminars in Immunopathology (2019)